Shining Path?

  • by: |
  • 01/15/2013

FDA will hold a public hearing on Feb. 4-5 to obtain input on creating a new approval pathway for therapeutics for limited, well-defined subpopulations of patients with serious or life-threatening conditions, including infections caused by antibiotic-resistant bacteria. According to the agency, such a pathway could allow companies to evaluate safety and efficacy in subpopulations of patients with more serious manifestations of a condition. The result, said FDA, could be smaller, more rapid clinical trials than studies in a broader group of patients with a wide range of clinical manifestations. The agency said a narrow indication of therapeutics approved via such a pathway could be expanded based on additional data demonstrating efficacy and safety in a broader population.

FDA is seeking input on the need for and feasibility of such a pathway, as well as its potential advantages and disadvantages. The agency is asking stakeholders to discuss which diseases or conditions would benefit from such an approval pathway, as well as whether the pathway would increase the number of therapeutic options in the context of the agency's existing expedited processes, including accelerated approval and the Fast Track program. FDA also is seeking input on how the agency could monitor use of drugs approved under the pathway. Comments are due March 1.


Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
Better Health
Biotech Blog
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
Envisioning 2.0
FDA Law Blog
Fierce Pharma
Fresh Air Fund
Furious Seasons
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
In the Pipeline
In Vivo
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
More than Medicine
National Review
Neuroethics & Law
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmacology Corner
Pharmaceutical Business Review
Piper Report
Prescription for a Cure
Public Plan Facts
Real Clear Politics
Shark Report
Shearlings Got Plowed
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog